$CELG Recent News How retail sector sets up st
Post# of 72711
Posted On: 08/27/2014 12:34:34 PM
$CELG Recent News
How retail sector sets up stocks at the end of summer 3:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 11:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 1:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 2:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 1:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 7:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 11:20 a.m. July 1, 2014 - Michael Ashbaugh
S&P, Dow rattle cage on uncharted territory 10:54 a.m. July 1, 2014 - Michael Ashbaugh
Celgene's fourth stock split is a hit with investors as shares climb 1:02 p.m. June 19, 2014 - Russ Britt
Celgene shareholders approve 2-for-1 stock split 8:57 a.m. June 19, 2014 - Ciara Linnane
Celgene to increase buyback program to 1.15 bln shares from 575 mln 8:52 a.m. June 19, 2014 - Ciara Linnane
Celgene shareholders approve 2-for-1 stock split 8:51 a.m. June 19, 2014 - Ciara Linnane
Celgene drops 1.9%, among worst S&P 500 losers 9:32 a.m. May 29, 2014 - Sue Chang
Higher rates are coming — here’s how you prepare 8:38 a.m. May 12, 2014 - Jeff Reeves
Wall Street up for second day on earnings cheer; biotechs rebound: Stock market live blog recap 4:03 p.m. April 29, 2014 - blogs.marketwatch.com
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog 10:32 a.m. Today - Zacks.com
Rising Short Interest in Biotech Stocks 9:42 a.m. Today - 247WallSt.com
Celgene, Gilead Lead Big Biotech Stock Movers 1:38 p.m. Aug. 26, 2014 - Investors Business Daily
Stock Market News for August 26, 2014 - Market News 10:10 a.m. Aug. 26, 2014 - Zacks.com
Why Celgene Stock Is Still A Good Investment Opportunity 9:05 a.m. Aug. 26, 2014 - Seeking Alpha
Pfizer, Merck Team Up on Cancer Study 8:42 a.m. Aug. 26, 2014 - The Wall Street Journal Interactive Edition
Biogen, Celgene In Buy Range; LinkedIn Coming Back 5:43 p.m. Aug. 25, 2014 - Investors Business Daily
Majority Of IBD 50 Firms Strong On Sponsorship 5:37 p.m. Aug. 22, 2014 - Investors Business Daily
Majority Of IBD 50 Firms Strong On Sponsorship 5:37 p.m. Aug. 22, 2014 - Investors Business Daily
Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog 5:35 p.m. Aug. 22, 2014 - Zacks.com
Cramer's Mad Money - 12 Stocks That Have Performed Better Than Google (8/21/14) 6:22 a.m. Aug. 22, 2014 - Seeking Alpha
Bull of the Day: Epizyme (EPZM) - Bull of the Day 1:31 a.m. Aug. 22, 2014 - Zacks.com
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog 5:20 p.m. Aug. 21, 2014 - Zacks.com
Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences 11:10 a.m. Aug. 21, 2014 - TheStreet.com
#PreMarket Primer: Thursday, August 21: Tension Between Russia And The West Mounting 5:40 a.m. Aug. 21, 2014 - benzinga.com
Jim Cramer's 'Mad Money' Recap: Where's the Economy Headed? Check the Railroads 8:08 p.m. Aug. 20, 2014 - TheStreet.com
Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog 6:08 p.m. Aug. 20, 2014 - Zacks.com
3 Drugs Stocks On The Rise 1:03 p.m. Aug. 20, 2014 - TheStreet.com
U.K. cost regulator backs Revlimid for bone marrow disorders 11:33 a.m. Aug. 20, 2014 - Seeking Alpha
Hottest Healthcare Stocks Now – ARIA CELG LCI RDY 9:15 a.m. Aug. 20, 2014 - InvestorPlace.com
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Celgene Corporation to Present at Investor Conferences in September 8:30 a.m. Aug. 21, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen 8:00 a.m. Aug. 20, 2014 - BusinessWire - BZX
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate 7:30 a.m. Aug. 19, 2014 - BusinessWire - BZX
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Critical Alerts For Advanced Micro Devices, Celgene, Weibo, SunPower, and Time Warner Released By InvestorsObserver 9:31 a.m. Aug. 5, 2014 - PR Newswire - PRF
Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis 7:00 a.m. July 9, 2014 - BusinessWire - BZX
Biotech Stocks Highlight -- Research on Celgene, Inovio Pharma, Amgen, and Array BioPharma 6:40 a.m. July 9, 2014 - PR Newswire - PRF
Clinical Trials, Petitions, and Upcoming Earnings Releases - Analyst Notes on Celgene, Covidien, AbbVie, Teva and Thermo Fisher Scientific 5:40 a.m. July 8, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Second Quarter 2014 Results on July 24, 2014 8:31 a.m. July 1, 2014 - BusinessWire - BZX
CORRECTING and REPLACINGCelgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake 2:28 p.m. June 26, 2014 - BusinessWire - BZX
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before 9:37 a.m. June 26, 2014 - ACCESSWIRE
Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake 8:30 a.m. June 26, 2014 - BusinessWire - BZX
Celgene Stockholders Approve Two-for-One Stock Split 8:30 a.m. June 19, 2014 - BusinessWire - BZX
Results from Phase III Study (AML-001) of VIDAZA® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA 8:58 a.m. June 14, 2014 - BusinessWire - BZX
Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in Beta-Thalassemia 3:00 a.m. June 14, 2014 - BusinessWire - BZX
Analysis of Health-Related Quality of Life Measures from the MM-020/IFM 07-01 (FIRST®) Trial Presented at EHA Annual Congress 5:44 p.m. June 13, 2014 - BusinessWire - BZX
Critical Alerts For JC Penney, Brown Forman, Schlumberger, Celgene, and DirecTV Technology Released By InvestorsObserver 9:31 a.m. June 11, 2014 - PR Newswire - PRF
Oral OTEZLA® (Apremilast) Showed Long-Term Clinical Benefits in Patients with Active Psoriatic Arthritis 7:30 a.m. June 11, 2014 - BusinessWire - BZX
Oral OTEZLA® (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Naïve Patients with Active Psoriatic Arthritis 7:30 a.m. June 11, 2014 - BusinessWire - BZX
How retail sector sets up stocks at the end of summer 3:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 11:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 1:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 2:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 1:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 7:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 11:20 a.m. July 1, 2014 - Michael Ashbaugh
S&P, Dow rattle cage on uncharted territory 10:54 a.m. July 1, 2014 - Michael Ashbaugh
Celgene's fourth stock split is a hit with investors as shares climb 1:02 p.m. June 19, 2014 - Russ Britt
Celgene shareholders approve 2-for-1 stock split 8:57 a.m. June 19, 2014 - Ciara Linnane
Celgene to increase buyback program to 1.15 bln shares from 575 mln 8:52 a.m. June 19, 2014 - Ciara Linnane
Celgene shareholders approve 2-for-1 stock split 8:51 a.m. June 19, 2014 - Ciara Linnane
Celgene drops 1.9%, among worst S&P 500 losers 9:32 a.m. May 29, 2014 - Sue Chang
Higher rates are coming — here’s how you prepare 8:38 a.m. May 12, 2014 - Jeff Reeves
Wall Street up for second day on earnings cheer; biotechs rebound: Stock market live blog recap 4:03 p.m. April 29, 2014 - blogs.marketwatch.com
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog 10:32 a.m. Today - Zacks.com
Rising Short Interest in Biotech Stocks 9:42 a.m. Today - 247WallSt.com
Celgene, Gilead Lead Big Biotech Stock Movers 1:38 p.m. Aug. 26, 2014 - Investors Business Daily
Stock Market News for August 26, 2014 - Market News 10:10 a.m. Aug. 26, 2014 - Zacks.com
Why Celgene Stock Is Still A Good Investment Opportunity 9:05 a.m. Aug. 26, 2014 - Seeking Alpha
Pfizer, Merck Team Up on Cancer Study 8:42 a.m. Aug. 26, 2014 - The Wall Street Journal Interactive Edition
Biogen, Celgene In Buy Range; LinkedIn Coming Back 5:43 p.m. Aug. 25, 2014 - Investors Business Daily
Majority Of IBD 50 Firms Strong On Sponsorship 5:37 p.m. Aug. 22, 2014 - Investors Business Daily
Majority Of IBD 50 Firms Strong On Sponsorship 5:37 p.m. Aug. 22, 2014 - Investors Business Daily
Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog 5:35 p.m. Aug. 22, 2014 - Zacks.com
Cramer's Mad Money - 12 Stocks That Have Performed Better Than Google (8/21/14) 6:22 a.m. Aug. 22, 2014 - Seeking Alpha
Bull of the Day: Epizyme (EPZM) - Bull of the Day 1:31 a.m. Aug. 22, 2014 - Zacks.com
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog 5:20 p.m. Aug. 21, 2014 - Zacks.com
Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences 11:10 a.m. Aug. 21, 2014 - TheStreet.com
#PreMarket Primer: Thursday, August 21: Tension Between Russia And The West Mounting 5:40 a.m. Aug. 21, 2014 - benzinga.com
Jim Cramer's 'Mad Money' Recap: Where's the Economy Headed? Check the Railroads 8:08 p.m. Aug. 20, 2014 - TheStreet.com
Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog 6:08 p.m. Aug. 20, 2014 - Zacks.com
3 Drugs Stocks On The Rise 1:03 p.m. Aug. 20, 2014 - TheStreet.com
U.K. cost regulator backs Revlimid for bone marrow disorders 11:33 a.m. Aug. 20, 2014 - Seeking Alpha
Hottest Healthcare Stocks Now – ARIA CELG LCI RDY 9:15 a.m. Aug. 20, 2014 - InvestorPlace.com
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Celgene Corporation to Present at Investor Conferences in September 8:30 a.m. Aug. 21, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen 8:00 a.m. Aug. 20, 2014 - BusinessWire - BZX
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate 7:30 a.m. Aug. 19, 2014 - BusinessWire - BZX
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Critical Alerts For Advanced Micro Devices, Celgene, Weibo, SunPower, and Time Warner Released By InvestorsObserver 9:31 a.m. Aug. 5, 2014 - PR Newswire - PRF
Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis 7:00 a.m. July 9, 2014 - BusinessWire - BZX
Biotech Stocks Highlight -- Research on Celgene, Inovio Pharma, Amgen, and Array BioPharma 6:40 a.m. July 9, 2014 - PR Newswire - PRF
Clinical Trials, Petitions, and Upcoming Earnings Releases - Analyst Notes on Celgene, Covidien, AbbVie, Teva and Thermo Fisher Scientific 5:40 a.m. July 8, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Second Quarter 2014 Results on July 24, 2014 8:31 a.m. July 1, 2014 - BusinessWire - BZX
CORRECTING and REPLACINGCelgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake 2:28 p.m. June 26, 2014 - BusinessWire - BZX
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before 9:37 a.m. June 26, 2014 - ACCESSWIRE
Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake 8:30 a.m. June 26, 2014 - BusinessWire - BZX
Celgene Stockholders Approve Two-for-One Stock Split 8:30 a.m. June 19, 2014 - BusinessWire - BZX
Results from Phase III Study (AML-001) of VIDAZA® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA 8:58 a.m. June 14, 2014 - BusinessWire - BZX
Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in Beta-Thalassemia 3:00 a.m. June 14, 2014 - BusinessWire - BZX
Analysis of Health-Related Quality of Life Measures from the MM-020/IFM 07-01 (FIRST®) Trial Presented at EHA Annual Congress 5:44 p.m. June 13, 2014 - BusinessWire - BZX
Critical Alerts For JC Penney, Brown Forman, Schlumberger, Celgene, and DirecTV Technology Released By InvestorsObserver 9:31 a.m. June 11, 2014 - PR Newswire - PRF
Oral OTEZLA® (Apremilast) Showed Long-Term Clinical Benefits in Patients with Active Psoriatic Arthritis 7:30 a.m. June 11, 2014 - BusinessWire - BZX
Oral OTEZLA® (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Naïve Patients with Active Psoriatic Arthritis 7:30 a.m. June 11, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼